Healthcare, Pharma & Life Sciences

San Francisco – October 14, 2026 -- Collective X Health (CX), a women's health and performance intelligence platform, has emerged from stealth with an oversubscribed $3.2 million pre-seed round co-led by Council Capital and Anthemis Female Innovators Lab Fund.

SoGal Ventures, Emerson Collective, Muse Capital and Segal Ventures also participated. The platform is live, with Human Powered Health and Altra Running as founding customers licensing its women's health intelligence via API for health, performance and recovery insights.

CX targets a research gap in AI-driven health products

CX argues that AI models trained on historical clinical research default to male data. Women were not required in NIH-funded clinical trials until 1993. According to the company, leading AI models failed 60% of questions on a recent women's health benchmark.

Conshohocken – October 14, 2026 -- Suvoda has made Sofia, its AI assistant on the Suvoda Platform, available for all new clinical trials using Suvoda RTSM/IRT or Suvoda eCOA, giving sponsors, CROs and sites faster access to trial data and the ability to act on it.

Sofia first launched with a group of early adopter companies that helped shape the product. The rollout extends it to every new trial on the two Suvoda products.

Sofia executes authorized system actions, not just queries

For authorized users, Sofia can carry out system actions in a single conversation. Before acting, it summarizes what it will do and asks for confirmation. Every action is attributed to the requesting user, governed by existing roles and permissions, and recorded in a full audit trail.

Providence – October 14, 2026 -- Highbar Physical Therapy has formally introduced three acquired practices as "Highbar Practices," creating a four-brand network that serves patients at 57 locations in Rhode Island and Massachusetts.

Three regional brands join Highbar's network under their existing names

The newly introduced practices are Joint Ventures Physical Therapy in Greater Boston, Peak Physical Therapy in the Greater South Shore, and Physical Therapy U in Southeastern Massachusetts and the South Coast. Highbar Physical Therapy itself operates in Rhode Island and in Southeastern and Central Massachusetts.

Peak joined Highbar in 2024. Joint Ventures Physical Therapy and Physical Therapy U followed in 2025.

Brentwood – October 14, 2026 -- Brookdale Senior Living (NYSE: BKD) agreed to buy the real estate of 30 communities it leases from Welltower for $290 million. The deal would cut 2027 annual cash rent by approximately $17.8 million and lift Brookdale's owned share of consolidated units to nearly 80%.

Brookdale closes $157M purchase of 17 formerly leased communities

Brookdale completed the previously announced acquisition on September 30 for approximately $157 million. The portfolio holds 735 assisted living and memory care units in Colorado, Kansas, Ohio and Texas.

The purchase eliminates approximately $11 million of annual cash rent in 2027 and raises Brookdale's owned share of consolidated units to approximately 77%.

Rochester, Mich. – October 14, 2026 -- Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level after detecting particulate matter in certain lots.

Particulates include cellulose, plastics and stopper material

The company identified the contaminants as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel. Par Health states that administering product containing particulate matter has a reasonable probability of causing life-threatening adverse health consequences.

The listed risks are pulmonary emboli, occlusions of other blood vessels that can lead to tissue death and possible organ damage, and inflammation of vein walls that may lead to clotting. To date, Par Health has received no reports of adverse events related to the recall.

Sheridan – October 14, 2026 -- The global sensor patch market is valued at USD 7.9 billion in 2026 and is projected to reach USD 28.9 billion by 2031, a CAGR of 29.6%, according to a study by Wissen Research.

Chronic disease burden drives demand for remote monitoring

Sensor patches are adhesive, skin-worn devices that measure signals such as glucose, cardiac activity, and temperature and transmit the data wirelessly to a smartphone, cloud platform, or clinician. The World Health Organization links chronic disease to about 41 million deaths a year, roughly 71% of all deaths worldwide. The International Diabetes Federation estimates that about 589 million adults aged 20-79 had diabetes in 2024.

As care shifts to remote and home settings, continuous glucose monitoring (CGM) and ambulatory cardiac patches are becoming core tools for managing long-term conditions outside the clinic.

CINCINNATI – October 14, 2026 -- Ten research areas, from gene editing to artificial intelligence, could drive the next generation of major advances in child health, according to a special article in Pediatric Research led by Tina Cheng, MD, MPH, who heads the Cincinnati Children's Research Foundation.

Four-physician team selects 10 research opportunities

Cheng worked with Stephen Daniels, MD, PhD, of Children's Hospital Colorado; Jessica Snowden, MD, MS, of the University of Tennessee Health Science Center; and Tracy Glauser, MD, associate director of the Cincinnati Children's Research Foundation. The article builds on a 2016 report on seven great achievements in child health research, which Cheng co-authored.

Priority list spans genetics, AI, vaccines and cancer

The 10 areas are:

Mount Pleasant, S.C. – October 14, 2026 -- Paradigm Therapeutics, Inc. has been named a finalist for the 2026 Prix Galien USA "Best Start-Up" Award, its second consecutive nomination after being a nominee in 2025.

The clinical-stage biopharmaceutical company is developing SD-101 (ZorblesiaTM), a topical cream for wounds and lesions across the entire skin surface in patients with Epidermolysis Bullosa (EB). The Galien Foundation manages the awards, which will be presented on October 14, 2026, at the American Museum of Natural History in New York City.

San Diego – – October 14, 2026 -- Inhibrx Biosciences (Nasdaq: INBX) will present phase 2 data on both clinical-stage candidates in its pipeline in four sessions at three oncology conferences between Oct. 25 and Nov. 20, 2026.

Ordastobart phase 2 primary analysis goes to ESMO on Oct. 25

The first session is an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid on Sunday, Oct. 25, from 8:30 to 10:00 AM CET. Lead author Jong Chul Park will present the phase 2 primary analysis of HexAgon-HN, a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) combined with pembrolizumab. The trial covers first-line treatment of PD-L1-high recurrent/metastatic head and neck squamous cell carcinoma.

Phoenix – October 14, 2026 -- Blue Cross Blue Shield of Arizona Health Choice (AZ Blue Health Choice) brought more than 200 tribal leaders, healthcare professionals, educators and partners to Flagstaff for the 13th Annual Tribal Summit, as the insurer serves members from 17 tribal nations.

Summit focuses on maternal, behavioral and workforce issues

The event, themed "Unity in Action: Bridging Systems, Strengthening Communities," centered on collaboration and shared learning to improve health outcomes across Arizona's tribal nations. Discussions covered maternal and child health, behavioral health, Indigenous health equity, workforce development and culturally responsive approaches to care.

Attendees shared best practices, explored emerging challenges and identified opportunities to strengthen support. The summit has served as a forum for tribal health leaders and organizations for more than a decade.